Actinium Pharmac Financials

ATNM

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Actinium Pharmac (ATNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 24 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Actinium Pharmac passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Actinium Pharmac generates $0.86 in operating cash flow (-$33.1M OCF vs -$38.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$41.9M

YoY+18.9%

Actinium Pharmac's EBITDA was -$41.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.9% from the prior year.

Free Cash Flow

-$33.1M

YoY+30.3%

Actinium Pharmac generated -$33.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 30.3% from the prior year.

Net Income

-$38.2M

YoY+21.7%

Actinium Pharmac reported -$38.2M in net income in fiscal year 2024. This represents an increase of 21.7% from the prior year.

EPS (Diluted)

$-1.27

YoY+30.6%

Actinium Pharmac earned $-1.27 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.6% from the prior year.

Cash & Debt

$72.9M

YoY-4.9%

5Y CAGR+51.1%

10Y CAGR+26.9%

Actinium Pharmac held $72.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+12.9%

Actinium Pharmac had 31M shares outstanding in fiscal year 2024. This represents an increase of 12.9% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$30.0M

YoY-22.3%

5Y CAGR+12.7%

10Y CAGR+9.4%

Actinium Pharmac invested $30.0M in research and development in fiscal year 2024. This represents a decrease of 22.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$11K

YoY-92.8%

5Y CAGR-29.7%

10Y CAGR-23.1%

Actinium Pharmac invested $11K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 92.8% from the prior year.

ATNM Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$81K-92.1%	$1.0M-10.0%	$1.1M	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	$900K	N/A	N/A
Gross Profit	N/A	N/A	N/A	$244K	N/A	N/A
R&D Expenses	$30.0M-22.3%	$38.7M+67.1%	$23.1M+28.3%	$18.0M+12.1%	$16.1M-2.8%	$16.6M
SG&A Expenses	$12.1M-9.4%	$13.3M+11.1%	$12.0M+48.6%	$8.1M+28.0%	$6.3M+14.2%	$5.5M
Operating Income	-$42.1M+18.9%	-$51.9M-52.2%	-$34.1M-36.6%	-$25.0M-11.5%	-$22.4M-1.5%	-$22.1M
Interest Expense	N/A	$3.1M+185.4%	$1.1M+472.1%	$190K+6.7%	$178K+3.5%	$172K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$38.2M+21.7%	-$48.8M-47.9%	-$33.0M-33.3%	-$24.8M-11.5%	-$22.2M-1.4%	-$21.9M
EPS (Diluted)	$-1.27+30.6%	$-1.83-33.6%	$-1.37-14.2%	$-1.20	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Revenue	$90K	N/A	N/A	N/A	$0-100.0%	$45K0.0%	$45K-95.2%	$940K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.2M-56.5%	$9.8M	N/A	$11.6M+58.5%	$7.3M+8.3%	$6.8M+45.2%	$4.7M+6.7%	$4.4M
SG&A Expenses	$1.5M-45.7%	$2.8M	N/A	$2.7M-31.1%	$4.0M+28.8%	$3.1M-4.9%	$3.2M+86.3%	$1.7M
Operating Income	-$5.7M+54.8%	-$12.6M	N/A	-$14.4M-27.1%	-$11.3M-15.2%	-$9.8M-24.8%	-$7.8M-52.0%	-$5.2M
Interest Expense	N/A	$927K	N/A	$1.1M+66.9%	$644K+98.2%	$325K+291.6%	$83K+137.1%	$35K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.1M+55.6%	-$11.6M	N/A	-$13.3M-24.7%	-$10.6M-12.4%	-$9.5M-22.0%	-$7.8M-51.4%	-$5.1M
EPS (Diluted)	$-0.16+56.8%	$-0.37	N/A	$-0.49-14.0%	$-0.43-13.2%	$-0.38-15.2%	$-0.33-43.5%	$-0.23

ATNM Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$76.9M-5.6%	$81.4M-28.7%	$114.2M+42.1%	$80.4M+21.1%	$66.4M+469.0%	$11.7M
Current Assets	$74.5M-4.8%	$78.3M-29.5%	$110.9M+39.1%	$79.7M+22.8%	$64.9M+543.6%	$10.1M
Cash & Equivalents	$72.9M-4.9%	$76.7M-29.6%	$108.9M+39.9%	$77.8M+22.4%	$63.6M+586.8%	$9.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$44.1M-2.1%	$45.1M-5.5%	$47.7M+597.2%	$6.8M+34.8%	$5.1M-15.7%	$6.0M
Current Liabilities	$8.1M-4.1%	$8.5M-20.1%	$10.6M+55.4%	$6.8M+43.5%	$4.8M-10.8%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$900K
Total Equity	$32.8M-10.0%	$36.4M-45.3%	$66.5M-9.6%	$73.5M+19.9%	$61.3M+986.4%	$5.6M
Retained Earnings	-$375.8M-11.3%	-$337.6M-16.9%	-$288.8M-12.9%	-$255.7M-10.7%	-$231.0M-10.6%	-$208.8M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Total Assets	$56.2M-27.0%	$76.9M-5.6%	$81.4M-8.4%	$88.9M-22.1%	$114.2M-2.2%	$116.8M-4.1%	$121.8M+63.4%	$74.6M
Current Assets	$54.4M-27.0%	$74.5M-4.8%	$78.3M-8.6%	$85.6M-22.8%	$110.9M-2.2%	$113.4M-4.1%	$118.3M+59.7%	$74.1M
Cash & Equivalents	$53.4M-26.8%	$72.9M-4.9%	$76.7M-7.6%	$83.0M-23.8%	$108.9M-2.6%	$111.8M-3.9%	$116.3M+61.5%	$72.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$42.4M-4.0%	$44.1M-2.1%	$45.1M-0.7%	$45.4M-4.9%	$47.7M+4.7%	$45.6M+4.5%	$43.6M+661.9%	$5.7M
Current Liabilities	$6.8M-16.1%	$8.1M-4.1%	$8.5M-2.1%	$8.7M-18.4%	$10.6M+27.3%	$8.3M+32.9%	$6.3M+9.8%	$5.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$13.8M-57.9%	$32.8M-10.0%	$36.4M-16.5%	$43.6M-34.4%	$66.5M-6.7%	$71.3M-8.9%	$78.2M+13.6%	$68.8M
Retained Earnings	-$403.8M-7.4%	-$375.8M-11.3%	-$337.6M-2.8%	-$328.3M-13.7%	-$288.8M-3.8%	-$278.1M-3.5%	-$268.6M-3.0%	-$260.9M

ATNM Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$33.1M+30.1%	-$47.3M-647.6%	$8.6M+141.4%	-$20.9M+3.5%	-$21.6M-0.7%	-$21.5M
Capital Expenditures	$11K-92.8%	$153K-58.2%	$366K+175.2%	$133K-47.4%	$253K+295.3%	$64K
Free Cash Flow	-$33.1M+30.3%	-$47.5M-673.7%	$8.3M+139.4%	-$21.0M+4.0%	-$21.9M-1.6%	-$21.5M
Investing Cash Flow	-$11K+92.8%	-$153K+58.2%	-$366K-175.2%	-$133K+47.4%	-$253K-295.3%	-$64K
Financing Cash Flow	$29.3M+97.2%	$14.9M-35.7%	$23.1M-34.4%	$35.2M-53.8%	$76.2M+345.1%	$17.1M
Dividends Paid	N/A	N/A	$0	$0	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Operating Cash Flow	-$6.3M-10.0%	-$5.8M+23.2%	-$7.5M+32.7%	-$11.1M-43.0%	-$7.8M-36.1%	-$5.7M-120.5%	$27.9M+582.9%	-$5.8M
Capital Expenditures	N/A	$0	$0-100.0%	$30K+87.5%	$16K-78.1%	$73K-73.0%	$270K+3757.1%	$7K
Free Cash Flow	N/A	-$5.8M+23.2%	-$7.5M+32.9%	-$11.2M-43.1%	-$7.8M-34.7%	-$5.8M-120.9%	$27.6M+577.7%	-$5.8M
Investing Cash Flow	N/A	$0	$0+100.0%	-$30K-87.5%	-$16K+78.1%	-$73K+73.0%	-$270K-3757.1%	-$7K
Financing Cash Flow	-$209K-6866.7%	-$3K-100.3%	$1.2M-58.3%	$2.9M-41.5%	$4.9M+210.7%	$1.6M-90.5%	$16.7M+75840.9%	-$22K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATNM Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	21.3%	N/A	N/A
Operating Margin	N/A	-64098.8%-60787.7pp	-3311.1%-1128.9pp	-2182.2%	N/A	N/A
Net Margin	N/A	-60269.1%-57063.6pp	-3205.5%-1040.0pp	-2165.6%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-49.7%+10.2pp	-59.9%-31.0pp	-28.9%+1.9pp	-30.8%+2.6pp	-33.5%+154.2pp	-187.7%
Current Ratio	9.14-0.1	9.21-1.2	10.44-1.2	11.66-2.0	13.62+11.7	1.89
Debt-to-Equity	1.35+0.1	1.24+0.5	0.72+0.6	0.09+0.0	0.08-0.1	0.16
FCF Margin	N/A	-58627.2%-59430.8pp	803.7%+2639.3pp	-1835.6%	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-6324.4%	N/A	N/A	N/A	N/A	-21775.6%-4331.1pp	-17444.4%-16895.1pp	-549.4%
Net Margin	-5701.1%	N/A	N/A	N/A	N/A	-21053.3%-3793.3pp	-17260.0%-16714.4pp	-545.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-9.1%+5.0pp	-14.1%	N/A	-14.9%-5.6pp	-9.3%-1.2pp	-8.1%-1.7pp	-6.4%+0.5pp	-6.9%
Current Ratio	7.96-1.2	9.14-0.1	9.21-0.7	9.87-0.6	10.44-3.1	13.58-5.2	18.83+5.9	12.94
Debt-to-Equity	3.07+1.7	1.35+0.1	1.24+0.2	1.04+0.3	0.72+0.1	0.64+0.1	0.56+0.5	0.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	-12862.2%-74302.2pp	61440.0%+62055.7pp	-615.7%

Similar Companies

Pds Biotechnology Corporation PDSB

$37.1M

Polypid Ltd. PYPD

$80.3M

Vtv Therapeutics VTVT

$145.4M

Genenta Science Spa GNTA

$21.1M

Cue Biopharma Inc CUE

$26.6M

Frequently Asked Questions

Is Actinium Pharmac profitable?

No, Actinium Pharmac (ATNM) reported a net income of -$38.2M in fiscal year 2024.

What is Actinium Pharmac's earnings per share (EPS)?

Actinium Pharmac (ATNM) reported diluted earnings per share of $-1.27 for fiscal year 2024. This represents a 30.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Actinium Pharmac's EBITDA?

Actinium Pharmac (ATNM) had EBITDA of -$41.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Actinium Pharmac's free cash flow?

Actinium Pharmac (ATNM) generated -$33.1M in free cash flow during fiscal year 2024. This represents a 30.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Actinium Pharmac's operating cash flow?

Actinium Pharmac (ATNM) generated -$33.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Actinium Pharmac's total assets?

Actinium Pharmac (ATNM) had $76.9M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Actinium Pharmac's capital expenditures?

Actinium Pharmac (ATNM) invested $11K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Actinium Pharmac spend on research and development?

Actinium Pharmac (ATNM) invested $30.0M in research and development during fiscal year 2024.

How many shares does Actinium Pharmac have outstanding?

Actinium Pharmac (ATNM) had 31M shares outstanding as of fiscal year 2024.

What is Actinium Pharmac's current ratio?

Actinium Pharmac (ATNM) had a current ratio of 9.14 as of fiscal year 2024, which is generally considered healthy.

What is Actinium Pharmac's debt-to-equity ratio?

Actinium Pharmac (ATNM) had a debt-to-equity ratio of 1.35 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Actinium Pharmac's return on assets (ROA)?

Actinium Pharmac (ATNM) had a return on assets of -49.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Actinium Pharmac's cash runway?

Based on fiscal year 2024 data, Actinium Pharmac (ATNM) had $72.9M in cash against an annual operating cash burn of $33.1M. This gives an estimated cash runway of approximately 26 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Actinium Pharmac's Piotroski F-Score?

Actinium Pharmac (ATNM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Actinium Pharmac's earnings high quality?

Actinium Pharmac (ATNM) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.